The U.S. Food and Drug Administration approved a label expansion for VYVGART and VYVGART Hytrulo on May 8, 2026, extending treatment to all adults with generalized myasthenia gravis (gMG). The approval includes patients who are seronegative for anti-AChR antibodies, roughly 20% of the gMG population, many of whom had no FDA-approved targeted therapy specific to their antibody subtype.

Generalized myasthenia gravis is a chronic autoimmune neuromuscular disease that causes muscle weakness affecting daily activities, breathing, and swallowing. The expanded approval covers patients who test positive for anti-MuSK antibodies, anti-LRP4 antibodies, and those who are triple seronegative (negative for all three antibody types). VYVGART is now the first and only FDA-approved treatment that works across all adult gMG serotypes.

What Changed

Before this approval, VYVGART and VYVGART Hytrulo were approved only for adults with gMG who tested positive for anti-acetylcholine receptor (anti-AChR) antibodies. That covers about 80% of gMG patients. The remaining 20%, those who are seronegative for anti-AChR antibodies, relied on off-label immunosuppressants, corticosteroids, and supportive care without an FDA-approved targeted treatment designed for their specific antibody profile.

The Phase 3 ADAPT SERON study tested VYVGART in adults with gMG who don't have detectable anti-AChR antibodies. The study met its primary endpoint, showing that patients treated with VYVGART achieved a statistically significant improvement in daily living activities compared to placebo at week four (p=0.0068). Patients treated with VYVGART improved by an average of 3.35 points on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale at week four. Improvements were seen across all seronegative subgroups, including anti-MuSK-positive, anti-LRP4-positive, and triple seronegative patients.

Who Is Affected

This approval matters for adults with generalized myasthenia gravis who:

• Test negative for anti-AChR antibodies (about 20% of gMG patients)
• Test positive for anti-MuSK antibodies
• Test positive for anti-LRP4 antibodies
• Are triple seronegative (negative for all three antibody types)

VYVGART is given as an intravenous infusion. VYVGART Hytrulo is a subcutaneous injection formulation that can be self-administered at home using a prefilled syringe. Both formulations are approved under this expanded label.

The approval applies only to adults (18 and older). Myasthenia gravis can affect children, but VYVGART isn't approved for pediatric use at this time.

What This Means for Families

For families navigating gMG with a seronegative diagnosis, this approval removes the "no FDA-approved options" message that many have heard from their neurologists. It doesn't mean VYVGART is the right treatment for every seronegative patient. That's a decision your care team makes based on disease severity, antibody subtype, response to current therapies, and insurance coverage. It means there's now a targeted treatment that has been tested specifically in seronegative gMG patients and shown to improve daily function.

VYVGART works by reducing levels of IgG antibodies, including the pathogenic antibodies that attack the neuromuscular junction in gMG. The medication is given in treatment cycles. For the IV formulation, patients typically receive infusions once weekly for four weeks, followed by a treatment-free period before starting another cycle as needed. The subcutaneous formulation follows a similar cycle-based approach but can be administered at home.

Treatment isn't a cure. Myasthenia gravis remains a chronic condition that requires ongoing management. But for seronegative patients who've struggled to find effective therapies, having an FDA-approved option designed for their antibody profile gives neurologists a clearer clinical pathway.

What Families Can Do Now

If you or your family member has generalized myasthenia gravis and tests negative for anti-AChR antibodies, here's what to do next:

• Ask your neurologist whether VYVGART is appropriate for your antibody subtype. Bring documentation of your antibody test results (anti-AChR, anti-MuSK, anti-LRP4) to the appointment. Ask how VYVGART would fit into your current treatment plan and whether you'd be a candidate for the IV or subcutaneous formulation.

Where to Find More Information

The full prescribing information for VYVGART and VYVGART Hytrulo is available on the VYVGART healthcare provider website. The Myasthenia Gravis Foundation of America offers patient education resources, support groups, and advocacy information for families navigating gMG. The Muscular Dystrophy Association publishes updates on MG research and treatment access.

If you're already being treated for gMG with immunosuppressants, corticosteroids, or IVIG, don't stop those treatments without consulting your neurologist. VYVGART may be added to your existing regimen or used as a replacement therapy depending on your response and treatment goals. That decision is made between you and your care team based on your specific clinical situation.

The approval announcement from argenx is available on GlobeNewswire, and the Muscular Dystrophy Association's press release covers the clinical trial data and what the approval means for patients.